Abacavir Sulfate/Lamivudine Atlanta Medicare Dosage/Direction for Use

Therapy should be prescribed by a physician experienced in the management of HIV infection.
Adults and adolescents: The recommended dose of the fixed-dose combination Abacavir 600 mg / Lamivudine 300 mg tablets in adults and adolescents is one tablet once daily.
The fixed-dose combination Abacavir 600 mg / Lamivudine 300 mg tablets should not be administered to adults or adolescents who weigh less than 40 kg because it is a fixed-dose tablet that cannot be dose reduced.
The fixed-dose combination Abacavir 600 mg / Lamivudine 300 mg tablets can be taken with or without food.
The fixed-dose combination Abacavir 600 mg / Lamivudine 300 mg tablets should not be prescribed for patients requiring dosage adjustments. Separate preparations of abacavir or lamivudine are available in cases where discontinuation or dose adjustment of one of the active substances is indicated. In these cases the physician should refer to the individual product information for these medicinal products.
Renal impairment: The fixed-dose combination Abacavir 600 mg / Lamivudine 300 mg tablets is not recommended for use in patients with a creatinine clearance < 50 ml/min.
Hepatic impairment: No data are available in patients with moderate hepatic impairment, therefore the use of the fixed-dose combination Abacavir 600 mg / Lamivudine 300 mg tablets is not recommended unless judged necessary. In patients with mild and moderate hepatic impairment close monitoring is required, and if feasible, monitoring of abacavir plasma levels is recommended. The fixed-dose combination Abacavir 600 mg / Lamivudine 300 mg tablets is contraindicated in patients with severe hepatic impairment.
Elderly: No pharmacokinetic data are currently available in patients over 65 years of age. Special care is advised in this age group due to age associated changes such as the decrease in renal function and alteration of haematological parameters.
Children: The fixed-dose combination Abacavir 600 mg / Lamivudine 300 mg tablets is not recommended for treatment of children less than 12 years of age as the necessary dose adjustment cannot be made.